

Carrier screening report Donor 14408 Date of Birth: Sema4 ID: 22154701

Patient Information

Name: Donor 14408 Date of Birth: Sema4 ID: 22154701 Client ID: SEATSB-S458814325 Indication: Carrier Screening

Specimen Information

Specimen Type: Blood Date Collected: 08/03/2022 Date Received: 08/04/2022 Final Report: 08/17/2022

Referring Provider

Jeffrey Olliffe, M.D. Seattle Sperm Bank 4915 25th Avenue NE Suite 204W Seattle, WA, 98105 Fax: 206-466-4696

Expanded Carrier Screen (502 genes)

with Personalized Residual Risk

SUMMARY OF RESULTS AND RECOMMENDATIONS

Ositive	⊖ Negative
Carrier of Glycogen Storage Disease, Type II (AR)	Negative for all other genes tested
Associated gene(s): GAA	To view a full list of genes and diseases tested
Variant(s) Detected: c32-13T>G, Pathogenic, Heterozygous (one	please see Table 1 in this report
сору)	
Carrier of Mitochondrial Complex IV Deficiency (COX20-	
related) (AR)	
Associated gene(s): COX20	
Variant(s) Detected: c.157+3G>C, Likely Pathogenic,	
Heterozygous (one copy)	
Carrier of Spinal Muscular Atrophy (AR)	
Associated gene(s): SMN1	
Variant(s) Detected: Loss of one copy of SMN1	

AR=Autosomal recessive; XL=X-linked

Recommendations

- Testing the partner for the above positive disorder(s) and genetic counseling are recommended.
- Please note that for female carriers of X-linked diseases, follow-up testing of a male partner is not indicated.
- CGG repeat analysis of *FMR1* for fragile X syndrome is not performed on males as repeat expansion of premutation alleles is not expected in the male germline.
- Individuals of Asian, African, Hispanic and Mediterranean ancestry should also be screened for hemoglobinopathies by CBC and hemoglobin electrophoresis.
- Consideration of residual risk by ethnicity after a negative carrier screen is recommended for the other diseases on the panel, especially in the case of a positive family history for a specific disorder. Please note that residual risks for X-linked diseases (including full repeat expansions for Fragile X syndrome) may not be accurate for males and the actual residual risk is likely to be lower.

T: 800-298-6470 F: 646-859-6870 www.sema4.com



Interpretation of positive results

Glycogen Storage Disease, Type II (AR)

Results and Interpretation

A heterozygous (one copy) pathogenic intronic variant, c.-32-13T>G, was detected in the *GAA* gene (NM_000152.3). Individuals with this variant tend to have a later onset of the disease, slower progression and longer lifespan. While the age of onset can vary between infancy to more than 50 years of age, no patients with this variant have been reported to develop the classic infantile form of Pompe disease. Homozygotes for this variant are not expected to be affected with infantile Pompe disease, unless this variant is present as part of a complex allele. When this variant is present in trans with a pathogenic variant, it is considered to be causative for glycogen storage disease, type II. Therefore, this individual is expected to be at least a carrier for glycogen storage disease, type II. Heterozygous carriers are not expected to exhibit symptoms of this disease.

What is Glycogen Storage Disease, Type II?

Glycogen storage disease type II, also known as Pompe disease, is an autosomal recessive disorder that is caused by pathogenic variants in the gene *GAA*. While it is found in populations worldwide, it is most prevalent in individuals of Ashkenazi Jewish or African descent. Symptoms can manifest in infancy or later in life. There are two main forms of the disease.

- Infantile-onset disease is characterized by poor feeding and failure to thrive, hypotonia, and an enlarged heart. If untreated, the cardiac
 manifestations usually cause death in the first year of life. A variant form of the infantile-onset disease has a slower progression, with
 death in occurring in childhood. Enzyme replacement therapy may slow the disease progression.
- Late-onset disease can begin any time after infancy. These patients do not usually have cardiac problems, but have muscle weakness and difficulty breathing. Patients may reach adulthood, but life expectancy is reduced.

Specific variants have been associated with the infantile-onset or late-onset forms; however, the correlation is not always absolute, and some variants do not have a known genotype-phenotype correlation.

Mitochondrial Complex IV Deficiency (COX20-related) (AR)

Results and Interpretation

A heterozygous (one copy) likely pathogenic intronic variant, c.157+3G>C, was detected in the *COX20* gene (NM_198076.5). When this variant is present in trans with a pathogenic variant, it is considered to be causative for mitochondrial complex IV deficiency (*COX20*-related). Therefore, this individual is expected to be at least a carrier for mitochondrial complex IV deficiency (*COX20*-related). Heterozygous carriers are not expected to exhibit symptoms of this disease.

What is Mitochondrial Complex IV Deficiency (COX20-related)?

Mitochondrial complex IV deficiency is an autosomal recessive disorder caused by pathogenic variants in multiple genes, including *COX20*. The onset and severity of this condition varies from acute neurometabolic decompensation in late infancy to subtle neurological signs presenting in adolescence. Neurological deficiencies include loss of developmental milestones such as the ability to walk, sit, or speak, seizures, and spastic weakness in all extremities. Typically, the clinical course stabilizes, and marked recovery of developmental milestones has been observed. Some, but not all, individuals experience cognitive impairment. No clear genotype-phenotype correlation has been established.

Spinal Muscular Atrophy (AR)

Results and Interpretation SMN1 copy number: 1 SMN2 copy number: 2 c.*3+80T>G: Negative SMN1 Sequencing: Negative Gene(s) analyzed: SMN1 (NM_000344.3) and SMN2 (NM_017411.3)

Inheritance: Autosomal Recessive

This patient is positive for loss of one copy of *SMN1* and is, therefore, a carrier of spinal muscular atrophy (SMA). Complete loss of *SMN1* is causative for SMA. The status of the c.'3+80T>G SNP does not modify residual risk, as this patient was determined to have one copy of *SMN1* by MLPA analysis. Next generation sequencing of the *SMN1* gene did not identify any pathogenic or likely pathogenic variants.



What is spinal muscular atrophy?

Spinal muscular atrophy (SMA) is a pan-ethnic, autosomal recessive disease caused by loss of function of the *SMN1* gene. In over 95% of cases, patients are missing both copies of the *SMN1* gene. The disease is characterized by the degeneration of alpha motor neurons of the spinal cord anterior horn cells, leading to progressive symmetric weakness, atrophy of the proximal voluntary muscles and early death. Age of onset can be anywhere on a continuum from the prenatal period to adulthood.

- SMA 0 represents the most severe form. Infants are born with severe hypotonia and joint contractures; no motor milestones are achieved and patients die before 6 months of age.
- SMA I has an age of onset in the first six months of life. These cases are associated with death usually by age 2 and the lack of development of motor skills.
- SMA II has an age of onset between 3 and 15 months; patients may be able to sit independently. Intelligence is not affected. Life expectancy may vary from early childhood to early adulthood.
- SMA III has an age of onset after 18 months of age and as late as adolescence; patients may learn to stand and to walk short distances. These patients may have a normal lifespan.
- SMA IV is an adult-onset disorder of muscle weakness; life span is not shortened.

Most patients, regardless of the severity of disease, have a deletion of both *SMN1* copies. Patients with later-onset disease usually have three or more copies of *SMN2*, which encodes a small amount of residual protein and lessens the severity of the symptoms. However, other factors besides *SMN2* copy number may affect the phenotype, and therefore the severity of the disease may not be able to be accurately predicted in all patients based on genotype. New treatments may be available to infants and children to prevent development of symptoms and slow progression of the disease.

Test description

This patient was tested for a panel of diseases using a combination of sequencing, targeted genotyping and copy number analysis. Please note that negative results reduce but do not eliminate the possibility that this individual is a carrier for one or more of the disorders tested. Please see Table 1 for a list of genes and diseases tested with the patient's personalized residual risk. If personalized residual risk is not provided, please see the complete residual risk table at **go.sema4.com/residualrisk**. Only variants determined to be pathogenic or likely pathogenic are reported in this carrier screening test.

Alice K Tanner

Alice Tanner, Ph.D., M.S., CGC, FACMG, Laboratory Director Laboratory Medical Consultant: George A. Diaz, M.D., Ph.D



Genes and diseases tested

The personalized residual risks listed below are specific to this individual. The complete residual risk table is available at **go.sema4.com/residualrisk**

Table 1: List of genes and diseases tested with detailed results

	Disease	Gene	Inheritance Pattern	Status	Detailed Summary
9	Positive				
	Glycogen Storage Disease, Type II	GAA	AR	Carrier	c32-13T>G, Pathogenic, Heterozygous (one copy)
	Mitochondrial Complex IV Deficiency (<i>COX20</i> - related)	COX20	AR	Carrier	c.157+3G>C, Likely Pathogenic, Heterozygous (one copy)
	Spinal Muscular Atrophy	SMN1	AR	Carrier	<i>SMN1</i> copy number: 1 <i>SMN2</i> copy number: 2 c.*3+80T>G: Negative SMN1 Sequencing: Negative
)	Negative				
	2-Methylbutyrylglycinuria	ACADSB	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,000
	3-Beta-Hydroxysteroid Dehydrogenase Type II Deficiency	HSD3B2	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.300
	3-Methylcrotonyl-CoA Carboxylase Deficiency (<i>MCCC1</i> -Related)	MCCC1	AR	Reduced Risk	Personalized Residual Risk: 1 in 3,400
	3-Methylcrotonyl-CoA Carboxylase Deficiency (<i>MCCC2</i> -Related)	MCCC2	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,200
	3-Methylglutaconic Aciduria, Type III	OPA3	AR	Reduced Risk	Personalized Residual Risk: 1 in 8,300
	3-Phosphoglycerate Dehydrogenase Deficiency	PHGDH	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,200
	6-Pyruvoyl-Tetrahydropterin Synthase Deficiency	PTS	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,800
	CD59-Mediated Hemolytic Anemia	CD59	AR	Reduced Risk	Personalized Residual Risk: 1 in 415,000
	Abetalipoproteinemia	MTTP	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.200
	Achalasia-Addisonianism-Alacrimia Syndrome	AAAS	AR	Reduced Risk	Personalized Residual Risk: 1 in 4.500
	Achromatopsia (CNGA3-Related)	CNGA3	AR	Reduced Risk	Personalized Residual Risk: 1 in 150
	Achromatopsia (CNGB3-related)	CNGB3	AR	Reduced Risk	Personalized Residual Risk: 1 in 8,600
	Acrodermatitis Enteropathica	SLC39A4	AR	Reduced Risk	Personalized Residual Risk: 1 in 12,000
	Acute Infantile Liver Failure	TRMU	AR	Reduced Risk	Personalized Residual Risk: 1 in 9.400
	Acyl-CoA Oxidase I Deficiency	ACOX1	AR	Reduced Risk	Personalized Residual Risk: 1 in 39,000
	Adams-Oliver Syndrome 4	EOGT	AR	Reduced Risk	Personalized Residual Risk: 1 in 44,000
	Adenosine Deaminase Deficiency	ADA	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.100
	Adrenocorticotropic Hormone Deficiency	TBX19	AR	Reduced Risk	Personalized Residual Risk: 1 in 35.000
	Adrenoleukodystrophy, X-Linked	ABCD1	XL	Reduced Risk	Personalized Residual Risk: 1 in 19.000
	Agammaglobulinemia	BTK	XL	Reduced Risk	Personalized Residual Risk: 1 in 250,000
	Agenesis of the Corpus Callosum	FRMD4A	AR	Reduced Risk	Personalized Residual Risk: 1 in 420,000
	Aicardi-Goutieres Syndrome (<i>RNASEH2C-</i> Related)	RNASEH2C	AR	Reduced Risk	Personalized Residual Risk: 1 in 11,000
	Aicardi-Goutieres Syndrome (SAMHD1-Related)	SAMHD1	AR	Reduced Risk	Personalized Residual Risk: 1 in 10,000
	Aicardi-Goutieres Syndrome (TREX1-Related)	TREX1	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,500
	Albinism, Oculocutaneous, Type III	TYRP1	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.500
	Alkaptonuria	HGD	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,100
-	Alpha-Mannosidosis	MAN2B1	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,200



Carrier screening report Donor 14408 Date of Birth: Sema4 ID: 22154701

Alpha-Thalassemia	HBA1/HBA2	AR	Reduced Risk	HBA1 Copy Number: 2 HBA2 Copy Number: 2 No pathogenic copy number variants detected HBA1/ HBA2 Sequencing: Negative Personalized Residual Risk : 1 in 490
Alpha-Thalassemia Intellectual Disability Syndrome	ATRX	XL	Reduced Risk	Personalized Residual Risk: 1 in 48,000
Alport Syndrome (COL4A3-Related)	COL4A3	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,800
Alport Syndrome (COL4A4-Related)	COL4A4	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,800
Alport Syndrome (COL4A5-Related)	COL4A5	XL	Reduced Risk	Personalized Residual Risk: 1 in 150,000
Alstrom Syndrome	ALMS1	AR	Reduced Risk	Personalized Residual Risk: 1 in 3,800
Andermann Syndrome	SLC12A6	AR	Reduced Risk	Personalized Residual Risk: 1 in 76,000
Antley-Bixler Syndrome (POR-Related)	POR	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,000
Argininemia	ARG1	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,100
Argininosuccinic Aciduria	ASL	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,200
Aromatase Deficiency	CYP19A1	AR	Reduced Risk	Personalized Residual Risk: 1 in 5,400
Arthrogryposis, Intellectual Disability, and Seizures	SLC35A3	AR	Reduced Risk	Personalized Residual Risk: 1 in 336,000
Asparagine Synthetase Deficiency	ASNS	AR	Reduced Risk	Personalized Residual Risk: 1 in 21,000
Aspartylglycosaminuria	AGA	AR	Reduced Risk	Personalized Residual Risk: 1 in 13,000
Ataxia With Isolated Vitamin E Deficiency	TTPA	AR	Reduced Risk	Personalized Residual Risk: 1 in 61,000
Ataxia-Telangiectasia	ATM	AR	Reduced Risk	Personalized Residual Risk: 1 in 1.300
Ataxia-Telangiectasia-Like Disorder 1	MRE11	AR	Reduced Risk	Personalized Residual Risk: 1 in 5,500
Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay	SACS	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,600
Bardet-Biedl Syndrome (ARL6-Related)	ARL6	AR	Reduced Risk	Personalized Residual Risk: 1 in 20,000
Bardet-Biedl Syndrome (BBS10-Related)	BBS10	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,700
Bardet-Biedl Syndrome (BBS12-Related)	BBS12	AR	Reduced Risk	Personalized Residual Risk: 1 in 9,900
Bardet-Biedl Syndrome (BBS1-Related)	BBS1	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,400
Bardet-Biedl Syndrome (BBS2-Related)	BBS2	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,200
Bardet-Biedl Syndrome (BBS4-Related)	BBS4	AR	Reduced Risk	Personalized Residual Risk: 1 in 15.000
Bare Lymphocyte Syndrome, Type II	CIITA	AR	Reduced Risk	Personalized Residual Risk: 1 in 35.000
Barth Syndrome	TAZ	XL	Reduced Risk	Personalized Residual Risk: 1 in 183.000
Bartter Syndrome, Type 3	CLCNKB	AR	Reduced Risk	Personalized Residual Risk: 1 in 350
Bartter Syndrome, Type 4A	BSND	AR	Reduced Risk	Personalized Residual Risk: 1 in 91,000
Bernard-Soulier Syndrome, Type A1	GP1BA	AR	Reduced Risk	Personalized Residual Risk: 1 in 42,000
Bernard-Soulier Syndrome, Type C	GP9	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.300
Beta-Globin-Related Hemoglobinopathies	HBB	AR	Reduced Risk	Personalized Residual Risk (Beta-Globin- Related Hemoglobinopathies): 1 in 2,000 Personalized Residual Risk (Beta-Globin- Related Hemoglobinopathies: HbS Variant): 1 23,000 Personalized Residual Risk (Beta-Globin- Related Hemoglobinopathies: HbC Variant): 1 in 215,000
Beta-Ketothiolase Deficiency	ACATı	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,200
Beta-Mannosidosis	MANBA	AR	Reduced Risk	Personalized Residual Risk: 1 in 9,100
BH4-Deficient Hyperphenylalaninemia C	QDPR	AR	Reduced Risk	Personalized Residual Risk: 1 in 3,100
BH4-Deficient Hyperphenylalaninemia D	PCBD1	AR	Reduced Risk	Personalized Residual Risk: 1 in 8,000
Bilateral Frontoparietal Polymicrogyria	GPR56	AR	Reduced Risk	Personalized Residual Risk: 1 in 15,000
Biotinidase Deficiency	BTD	AR	Reduced Risk	Personalized Residual Risk: 1 in 500
BloomSyndrome	BLM	AR	Reduced Risk	Personalized Residual Risk: 1 in 7,400
Canavan Disease	ASPA	AR	Reduced Risk	Personalized Residual Risk: 1 in 4.000
Carbamoylphosphate Synthetase I Deficiency	CPS1	AR	Reduced Risk	Personalized Residual Risk: 1 in 1100



Carnitine Acylcarnitine Translocase Deficiency	SLC25A20	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,600
Carnitine Palmitoyltransferase IA Deficiency	CPT1A	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.500
Carnitine Palmitoyltransferase II Deficiency	CPT2	AR	Reduced Risk	Personalized Residual Risk: 1 in 670
Carpenter Syndrome	RAB23	AR	Reduced Risk	Personalized Residual Risk: 1 in 21,000
Cartilage-Hair Hypoplasia	RMRP	AR	Reduced Risk	Personalized Residual Risk: 1 in 960
Catecholaminergic Polymorphic Ventricular Tachycardia	CASQ2	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.900
Central Hypothyroidism and Testicular Enlargement	IGSF1	XL	Reduced Risk	Personalized Residual Risk: 1 in 781,000
Cerebral Creatine Deficiency Syndrome 1	SLC6A8	XL	Reduced Risk	Personalized Residual Risk: 1 in 208,000
Cerebral Creatine Deficiency Syndrome 2	GAMT	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,100
Cerebral Creatine Deficiency Syndrome 3	GATM	AR	Reduced Risk	Personalized Residual Risk: 1 in 7.900
Cerebral Dysgenesis, Neuropathy, Ichthyosis, and Palmoplantar Keratoderma Syndrome	SNAP29	AR	Reduced Risk	Personalized Residual Risk: 1 in 210,000
Cerebrotendinous Xanthomatosis	CYP27A1	AR	Reduced Risk	Personalized Residual Risk 1 in 3.900
Charcot-Marie-Tooth Disease, Type 4D	NDRG1	AR	Reduced Risk	Personalized Residual Risk: 1 in 730,000
Charcot-Marie-Tooth Disease, Type 5 / Arts Syndrome	PRPS1	XL	Reduced Risk	Personalized Residual Risk: 1 in 114,000
Charcot-Marie-Tooth Disease, X-Linked	GJB1	XL	Reduced Risk	Personalized Residual Risk: 1 in 11,000
Chediak-Higashi Syndrome	LYST	AR	Reduced Risk	Personalized Residual Risk: 1 in 7,100
Chondrodysplasia Punctata	ARSE	XL	Reduced Risk	Personalized Residual Risk: 1 in 862,000
Choreoacanthocytosis	VPS13A	AR	Reduced Risk	Personalized Residual Risk: 1 in 2.500
Choroideremia	CHM	XL	Reduced Risk	Personalized Residual Risk: 1 in 125,000
Chronic Granulomatous Disease (CYBA-Related)	CYBA	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.000
Chronic Granulomatous Disease (CYBB-Related)	CYBB	XL	Reduced Risk	Personalized Residual Risk: 1 in 294,000
Citrin Deficiency	SLC25A13	AR	Reduced Risk	Personalized Residual Risk: 1 in 12,000
Citrullinemia, Type 1	ASS1	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,500
Cockayne Syndrome, Type A	ERCC8	AR	Reduced Risk	Personalized Residual Risk: 1 in 8,900
Cockayne Syndrome, Type B and other <i>ERCC6</i> - Related Disorders	ERCC6	AR	Reduced Risk	Personalized Residual Risk: 1 in 8,100
Cohen Syndrome	VPS13B	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,400
Combined Factor V and VIII Deficiency	LMAN1	AR	Reduced Risk	Personalized Residual Risk: 1 in 102,000
Combined Malonic and Methylmalonic Aciduria	ACSF3	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,400
Combined Oxidative Phosphorylation Deficiency	GFM1	AR	Reduced Risk	Personalized Residual Risk: 1 in 13,000
Combined Oxidative Phosphorylation Deficiency 3	TSFM	AR	Reduced Risk	Personalized Residual Risk: 1 in 27,000
Combined Pituitary Hormone Deficiency 1	POU1F1	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.900
Combined Pituitary Hormone Deficiency 2	PROP1	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,800
Combined Pituitary Hormone Deficiency 3	LHX3	AR	Reduced Risk	Personalized Residual Risk: 1 in 140,000
Combined SAP Deficiency	PSAP	AR	Reduced Risk	Personalized Residual Risk: 1 in 44,000
Cone-Rod Dystrophy 6 / Leber Congenital Amaurosis 1	GUCY2D	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,200
Congenital Adrenal Hyperplasia due to 11-Beta- Hydroxylase Deficiency	CYP11B1	AR	Reduced Risk	Personalized Residual Risk: 1 in 520
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency	CYP17A1	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,800
Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency	CYP21A2	AR	Reduced Risk	CYP21A2 copy number: 2 CYP21A2 sequencing: Negative Personalized Residual Risk (Congenital Adrenal Hyperplasia due to 21-Hydroxylas Deficiency (Non-Classic)): 1 in 200 Personalized Residual Risk (Congenital Adrenal Hyperplasia due to 21-Hydroxylas Deficiency (Classic)): 1 in 1,300
Congenital Adrenal Hypoplasia (NRoB1 Related)	NR0B1	XL	Reduced Risk	Personalized Residual Risk 1 in 353,000
oungernation on attrij populatia (interse itelatea)				



MPL	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.100
AKR1D1	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,900
HSD3B7	AR	Reduced Risk	Personalized Residual Risk: 1 in 8,900
NGLY1	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.400
PMM2	AR	Reduced Risk	Personalized Residual Risk: 1 in 540
MPI	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.600
ALG6	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,100
DOLK	AR	Reduced Risk	Personalized Residual Risk: 1 in 134,000
SEC23B	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,000
CDAN1	AR	Reduced Risk	Personalized Residual Risk: 1 in 470
ABCA12	AR	Reduced Risk	Personalized Residual Risk: 1 in 5,100
NTRK1	AR	Reduced Risk	Personalized Residual Risk 1 in 5.700
LAMA2	AR	Reduced Risk	Personalized Residual Risk: 1 in 640
CHAT	AR	Reduced Risk	Personalized Residual Risk: 1 in 3,100
CHRNE	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,100
DOK7	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,200
RAPSN	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,900
			Personalized Residual Risk: 1 in 82,000
VPS45	AR	Reduced Risk	Personalized Residual Risk: 1 in 163,000
TSHR	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,000
TSHB	AR	Reduced Risk	Personalized Residual Risk: 1 in 118,000
SLC26A3	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,400
SLC4A11	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,100
CYP11B2	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,500
CFTR	AR	Reduced Risk	Personalized Residual Risk: 1 in 440
CTNS	AR	Reduced Risk	Personalized Residual Risk: 1 in 7.700
SLC3A1	AR	Reduced Risk	Personalized Residual Risk: 1 in 590
COX15	AR	Reduced Risk	Personalized Residual Risk: 1 in 3,300
HSD17B4	AR	Reduced Risk	Personalized Residual Risk: 1 in 5,000
MY015A	AR	Reduced Risk	Personalized Residual Risk: 1 in 240
PJVK	AR	Reduced Risk	Personalized Residual Risk: 1 in 15,000
TMC1	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,200
SYNE4	AR	Reduced Risk	Personalized Residual Risk: 1 in 43.000
LOXHD1	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,700
TMPRSS3	AR	Reduced Risk	Personalized Residual Risk: 1 in 510
OTOF	AR	Reduced Risk	Personalized Residual Risk: 1 in 630
CANT1	AR	Reduced Risk	Personalized Residual Risk: 1 in 7.700
DHCR24	AR	Reduced Risk	Personalized Residual Risk: 1 in 27.000
BMPER	AR	Reduced Risk	Personalized Residual Risk: 1 in 18,000
SLC4A1	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,000
DMD	XL	Reduced Risk	Personalized Residual Risk: 1 in 10,000
DKC1	XL	Reduced Risk	Personalized Residual Risk: 1 in 9.259.000
RTEL1	AR	Reduced Risk	Personalized Residual Risk: 1 in 9,800
	AKR1D1 HSD3B7 NGLY1 PMM2 MPI ALG6 DOLK SEC23B CDAN1 ABCA12 NTRK1 LAMA2 CHAT CHAT DOK7 RAPSN HAX1 VPS45 TSHR SLC26A3 SLC26A3 SLC26A3 SLC26A3 SLC26A3 SLC26A3 SLC3A1 CYP1B2 CFTR CTNS SLC3A1 COX15 HSD17B4 MY015A PJVK TMC1 SYNE4 LOXHD1 TMPRS53 OTOF CANT1 DHCR24 BMPER SLC4A1 DMD	AKR1D1 AR HSD3B7 AR NGLY1 AR PMM2 AR MPI AR ALG6 AR DOLK AR SEC23B AR CDAN1 AR ABCA12 AR LAMA2 AR CHAT AR DOK7 AR TSHR AR VPS45 AR SLC26A3 AR TSHR AR SLC26A3 AR CFTR AR SLC26A3 AR CFTR AR CFTR AR CDX5 AR HSD17B4 AR COX15 AR DVK AR TMC1 AR COX15 AR DVK AR DVK AR TMPRSS3 AR DHCR24 AR DHCR24 AR DHCR24 AR DMD XL DKC1 XL	AKR1D1ARReduced RiskHSD3B7ARReduced RiskNGLY1ARReduced RiskPMM2ARReduced RiskMPIARReduced RiskALG6ARReduced RiskDOLKARReduced RiskSEC23BARReduced RiskCDAN1ARReduced RiskABCA12ARReduced RiskCDAN1ARReduced RiskCDAN1ARReduced RiskCHATARReduced RiskCHATARReduced RiskCHATARReduced RiskDOK7ARReduced RiskDOK7ARReduced RiskFSHBARReduced RiskSLC26A3ARReduced RiskSLC26A3ARReduced RiskSLC26A3ARReduced RiskSLC26A3ARReduced RiskCTTNSARReduced RiskCTTNSARReduced RiskSLC26A3ARReduced RiskCYP11B2ARReduced RiskCTTNSARReduced RiskCDX15ARReduced RiskCTTNSARReduced RiskCTTNSARReduced RiskCTTNSARReduced RiskCDX1ARReduced RiskDHC1ARReduced RiskDHC1ARReduced RiskDMDXLReduced RiskDMDXLReduced RiskDMDXLReduced Risk



Ehlers-Danlos Syndrome, Type VI	PLOD1	AR	Reduced Risk	Personalized Residual Risk: 1 in 15.000
Ehlers-Danlos Syndrome, Type VIIC	ADAMTS2	AR	Reduced Risk	Personalized Residual Risk: 1 in 243.000
Ellis-Van Creveld Syndrome (EVC2-Related)	EVC2	AR	Reduced Risk	Personalized Residual Risk: 1 in 6.300
Ellis-van Creveld Syndrome (EVC-Related)	EVC	AR	Reduced Risk	Personalized Residual Risk: 1 in 4.200
Emery-Dreifuss Myopathy 1	EMD	XL	Reduced Risk	Personalized Residual Risk: 1 in 833.000
Enhanced S-Cone Syndrome	NR2E3	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,600
Ethylmalonic Encephalopathy	ETHE1	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.400
Fabry Disease	GLA	XL	Reduced Risk	Personalized Residual Risk: 1 in 7.700
Factor IX Deficiency	F9	XL	Reduced Risk	Personalized Residual Risk: 1 in 5.100
Factor VII Deficiency	F7	AR	Reduced Risk	Personalized Residual Risk: 1 in 450
Factor XI Deficiency	F11	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,500
Familial Autosomal Recessive Hypercholesterolemia	LDLRAP1	AR	Reduced Risk	Personalized Residual Risk: 1 in 136,000
Familial Dysautonomia	IKBKAP	AR	Reduced Risk	Personalized Residual Risk: 1 in 51,000
Familial Hypercholesterolemia	LDLR	AR	Reduced Risk	Personalized Residual Risk: 1 in 280
Familial Hyperinsulinemic Hypoglycemia 4 / 3- Hydroxyacyl-CoA Dehydrogenase Deficiency	HADH	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,000
Familial Hyperinsulinism (ABCC8-Related)	ABCC8	AR	Reduced Risk	Personalized Residual Risk: 1 in 450
Familial Hyperinsulinism (KCNJ11-Related)	KCNJ11	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.300
Familial Hyperphosphatemic Tumoral Calcinosis	GALNT3	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,100
Familial Mediterranean Fever	MEFV	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,200
Fanconi Anemia, Group A	FANCA	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,100
Fanconi Anemia, Group C	FANCC	AR	Reduced Risk	Personalized Residual Risk: 1 in 12,000
Fanconi Anemia, Group G	FANCG	AR	Reduced Risk	Personalized Residual Risk: 1 in 28,000
Fanconi-Bickel Syndrome	SLC2A2	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,500
Fragile X Syndrome	FMR1	XL	Reduced Risk	FMR1 CGG repeat sizes: Not Performed FMR1 Sequencing: Negative Fragile X CGG triplet repeat expansion testi was not performed at this time, as the patien has either been previously tested or is a ma Personalized Residual Risk : 1 in 19,000
Fructose-1,6-Bisphosphatase Deficiency	FBP1	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,600
Fucosidosis	FUCA1	AR	Reduced Risk	Personalized Residual Risk: 1 in 9,200
Fumarase Deficiency	FH	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,500
Fundus Albipunctatus	884			
	RDH5	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,000
Galactokinase Deficiency	GALK1	AR AR	Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 2,000 Personalized Residual Risk: 1 in 2,700
Galactokinase Deficiency Galactose Epimerase Deficiency				
	GALK1	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,700
Galactose Epimerase Deficiency	GALK1 GALE	AR AR	Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 2,700 Personalized Residual Risk: 1 in 5,600
Galactose Epimerase Deficiency Galactosemia	GALK1 GALE GALT	AR AR AR	Reduced Risk Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 2.700 Personalized Residual Risk: 1 in 5.600 Personalized Residual Risk: 1 in 3.200
Galactose Epimerase Deficiency Galactosemia Galactosialidosis	GALKI GALE GALT CTSA	AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 2700 Personalized Residual Risk: 1 in 5600 Personalized Residual Risk: 1 in 3200 Personalized Residual Risk: 1 in 7900
Galactose Epimerase Deficiency Galactosemia Galactosialidosis Gaucher Disease Generalized Thyrotropin-Releasing Hormone	GALKI GALE GALT CTSA GBA	AR AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 2.700 Personalized Residual Risk: 1 in 5.600 Personalized Residual Risk: 1 in 3.200 Personalized Residual Risk: 1 in 7.900 Personalized Residual Risk: 1 in 1.300
Galactose Epimerase Deficiency Galactosemia Galactosialidosis Gaucher Disease Generalized Thyrotropin-Releasing Hormone Resistance	GALK1 GALE GALT CTSA GBA TRHR	AR AR AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 2.700 Personalized Residual Risk: 1 in 5.600 Personalized Residual Risk: 1 in 3.200 Personalized Residual Risk: 1 in 7.900 Personalized Residual Risk: 1 in 7.900 Personalized Residual Risk: 1 in 1.300 Personalized Residual Risk: 1 in 1.4000
Galactose Epimerase Deficiency Galactosemia Galactosialidosis Gaucher Disease Generalized Thyrotropin-Releasing Hormone Resistance Geroderma Osteodysplasticum	GALK1 GALE GALT CTSA GBA TRHR GORAB	AR AR AR AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 2,700 Personalized Residual Risk: 1 in 5,600 Personalized Residual Risk: 1 in 3,200 Personalized Residual Risk: 1 in 7,900 Personalized Residual Risk: 1 in 1,300 Personalized Residual Risk: 1 in 1,300 Personalized Residual Risk: 1 in 1,000 Personalized Residual Risk: 1 in 70,000
Galactose Epimerase Deficiency Galactosemia Galactosialidosis Gaucher Disease Generalized Thyrotropin-Releasing Hormone Resistance Geroderma Osteodysplasticum Gitelman Syndrome	GALK1 GALE GALT CTSA GBA TRHR GORAB SLC12A3	AR AR AR AR AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 2,700 Personalized Residual Risk: 1 in 5,600 Personalized Residual Risk: 1 in 3,200 Personalized Residual Risk: 1 in 3,200 Personalized Residual Risk: 1 in 7,900 Personalized Residual Risk: 1 in 1,300 Personalized Residual Risk: 1 in 1,300 Personalized Residual Risk: 1 in 104,000 Personalized Residual Risk: 1 in 70,000 Personalized Residual Risk: 1 in 290
Galactose Epimerase Deficiency Galactosemia Galactosialidosis Gaucher Disease Generalized Thyrotropin-Releasing Hormone Resistance Geroderma Osteodysplasticum Gitelman Syndrome Glanzmann Thrombasthenia (<i>ITGA2B</i> -Related)	GALK1 GALE GALT CTSA GBA TRHR GORAB SLC12A3 TTGA2B	AR AR AR AR AR AR AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 2.700 Personalized Residual Risk: 1 in 5.600 Personalized Residual Risk: 1 in 3.200 Personalized Residual Risk: 1 in 7.900 Personalized Residual Risk: 1 in 7.900 Personalized Residual Risk: 1 in 1.300 Personalized Residual Risk: 1 in 104,000 Personalized Residual Risk: 1 in 70,000 Personalized Residual Risk: 1 in 290 Personalized Residual Risk: 1 in 1800
Galactose Epimerase Deficiency Galactosemia Galactosialidosis Gaucher Disease Generalized Thyrotropin-Releasing Hormone Resistance Geroderma Osteodysplasticum Gitelman Syndrome Glanzmann Thrombasthenia (<i>ITGA2B</i> -Related) Glanzmann Thrombasthenia (<i>ITGB3</i> -Related)	GALK1 GALE GALT CTSA GBA TRHR GORAB SLC12A3 ITGA2B ITGB3	AR AR AR AR AR AR AR AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 2,700 Personalized Residual Risk: 1 in 5,600 Personalized Residual Risk: 1 in 3,200 Personalized Residual Risk: 1 in 3,200 Personalized Residual Risk: 1 in 7,900 Personalized Residual Risk: 1 in 1,300 Personalized Residual Risk: 1 in 1,000 Personalized Residual Risk: 1 in 70,000 Personalized Residual Risk: 1 in 70,000 Personalized Residual Risk: 1 in 2,90 Personalized Residual Risk: 1 in 1,800 Personalized Residual Risk: 1 in 1,600
Galactose Epimerase Deficiency Galactosemia Galactosialidosis Gaucher Disease Generalized Thyrotropin-Releasing Hormone Resistance Geroderma Osteodysplasticum Gitelman Syndrome Glanzmann Thrombasthenia (<i>ITGA2B</i> -Related) Glutaric Acidemia, Type I	GALK1 GALE GALT CTSA GBA TRHR GORAB SLC12A3 TTGA2B TTGB3 GCDH	AR AR AR AR AR AR AR AR AR AR AR AR	Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 2,700 Personalized Residual Risk: 1 in 5,600 Personalized Residual Risk: 1 in 3,200 Personalized Residual Risk: 1 in 3,200 Personalized Residual Risk: 1 in 7,900 Personalized Residual Risk: 1 in 1,300 Personalized Residual Risk: 1 in 1,000 Personalized Residual Risk: 1 in 104,000 Personalized Residual Risk: 1 in 70,000 Personalized Residual Risk: 1 in 2,90 Personalized Residual Risk: 1 in 1,800 Personalized Residual Risk: 1 in 1,600 Personalized Residual Risk: 1 in 2,700
Galactose Epimerase Deficiency Galactosemia Galactosialidosis Gaucher Disease Generalized Thyrotropin-Releasing Hormone Resistance Geroderma Osteodysplasticum Gitelman Syndrome Glanzmann Thrombasthenia (<i>ITGA2B</i> -Related) Glutaric Acidemia, Type I Glutaric Acidemia, Type IIa	GALK1 GALE GALT CTSA GBA TRHR GORAB SLC12A3 TTGA2B TTGA2B TTGB3 GCDH ETFA	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 2,700 Personalized Residual Risk: 1 in 5,600 Personalized Residual Risk: 1 in 3,200 Personalized Residual Risk: 1 in 3,200 Personalized Residual Risk: 1 in 7,900 Personalized Residual Risk: 1 in 1,300 Personalized Residual Risk: 1 in 104,000 Personalized Residual Risk: 1 in 104,000 Personalized Residual Risk: 1 in 70,000 Personalized Residual Risk: 1 in 290 Personalized Residual Risk: 1 in 1800 Personalized Residual Risk: 1 in 1600 Personalized Residual Risk: 1 in 2,700 Personalized Residual Risk: 1 in 4,700
Galactose Epimerase Deficiency Galactosemia Galactosialidosis Gaucher Disease Generalized Thyrotropin-Releasing Hormone Resistance Geroderma Osteodysplasticum Gitelman Syndrome Glanzmann Thrombasthenia (<i>ITGA2B</i> -Related) Glutaric Acidemia, Type I Glutaric Acidemia, Type IIa Glutaric Acidemia, Type IIb	GALK1 GALE GALT CTSA GBA TRHR GORAB SLC12A3 ITGA2B ITGB3 GCDH ETFA ETFB	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 2,700 Personalized Residual Risk: 1 in 5,600 Personalized Residual Risk: 1 in 3,200 Personalized Residual Risk: 1 in 3,200 Personalized Residual Risk: 1 in 7,900 Personalized Residual Risk: 1 in 1,300 Personalized Residual Risk: 1 in 1,000 Personalized Residual Risk: 1 in 104,000 Personalized Residual Risk: 1 in 70,000 Personalized Residual Risk: 1 in 70,000 Personalized Residual Risk: 1 in 2,000 Personalized Residual Risk: 1 in 1,600 Personalized Residual Risk: 1 in 2,700 Personalized Residual Risk: 1 in 4,700 Personalized Residual Risk: 1 in 5,900
Galactose Epimerase Deficiency Galactosemia Galactosialidosis Gaucher Disease Generalized Thyrotropin-Releasing Hormone Resistance Geroderma Osteodysplasticum Gitelman Syndrome Glanzmann Thrombasthenia (<i>ITGA2B</i> -Related) Glutaric Acidemia, Type I Glutaric Acidemia, Type IIa Glutaric Acidemia, Type IIb Glutaric Acidemia, Type IIc	GALK1 GALE GALT CTSA GBA TRHR GORAB SLC12A3 TTGA2B TTGA2B TTGB3 GCDH ETFA ETFB ETFDH	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 2,700 Personalized Residual Risk: 1 in 5,600 Personalized Residual Risk: 1 in 3,200 Personalized Residual Risk: 1 in 3,200 Personalized Residual Risk: 1 in 7,000 Personalized Residual Risk: 1 in 1,300 Personalized Residual Risk: 1 in 1,000 Personalized Residual Risk: 1 in 104,000 Personalized Residual Risk: 1 in 70,000 Personalized Residual Risk: 1 in 70,000 Personalized Residual Risk: 1 in 70,000 Personalized Residual Risk: 1 in 2,000 Personalized Residual Risk: 1 in 1,600 Personalized Residual Risk: 1 in 2,700 Personalized Residual Risk: 1 in 2,700 Personalized Residual Risk: 1 in 1,700 Personalized Residual Risk: 1 in 5,900 Personalized Residual Risk: 1 in 1,700



Glycogen Storage Disease, Type 0	GYS2	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,200
Glycogen Storage Disease, Type Ia	G6PC	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.100
Glycogen Storage Disease, Type Ib	SLC37A4	AR	Reduced Risk	Personalized Residual Risk: 1 in 7,300
Glycogen Storage Disease, Type III	AGL	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.600
Glycogen Storage Disease, Type IV / Adult Polyglucosan Body Disease	GBE1	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,400
Glycogen Storage Disease, Type IXb	PHKB	AR	Reduced Risk	Personalized Residual Risk: 1 in 700
Glycogen Storage Disease, Type V	PYGM	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,200
Glycogen Storage Disease, Type VI	PYGL	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,600
Glycogen Storage Disease, Type VII	PFKM	AR	Reduced Risk	Personalized Residual Risk: 1 in 4.300
GRACILE Syndrome and Other <i>BCS1L</i> -Related Disorders	BCS1L	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.900
Gray Platelet Syndrome	NBEAL2	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,800
Growth Hormone Deficiency, Type IB	GHRHR	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.900
Hemochromatosis, Type 2A	HFE2	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.300
Hemochromatosis, Type 3	TFR2	AR	Reduced Risk	Personalized Residual Risk: 1 in 11,000
Hereditary Fructose Intolerance	ALDOB	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,900
Hereditary Spastic Paraparesis 49	TECPR2	AR	Reduced Risk	Personalized Residual Risk: 1 in 116,000
Hermansky-Pudlak Syndrome, Type 1	HPS1	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.500
Hermansky-Pudlak Syndrome, Type 3	HPS3	AR	Reduced Risk	Personalized Residual Risk: 1 in 49,000
Hermansky-Pudlak Syndrome, Type 4	HPS4	AR	Reduced Risk	Personalized Residual Risk: 1 in 35.000
Hermansky-Pudlak Syndrome, Type 6	HPS6	AR	Reduced Risk	Personalized Residual Risk: 1 in 9,400
HMG-CoA Lyase Deficiency	HMGCL	AR	Reduced Risk	Personalized Residual Risk: 1 in 2.700
Hmg-CoA Synthase 2 Deficiency	HMGCS2	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,000
Holocarboxylase Synthetase Deficiency	HLCS	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.500
Homocystinuria (<i>CBS</i> -Related)	CBS	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,400
Homocystinuria due to MTHFR Deficiency	MTHFR	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,300
Homocystinuria, cblE Type	MTRR	AR	Reduced Risk	Personalized Residual Risk: 1 in 9,600
Homocystinuria-Megaloblastic Anemia, Cobalamin G Type	MTR	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,100
Hydrocephalus	L1CAM	XL	Reduced Risk	Personalized Residual Risk: 1 in 40,000
Hydrolethalus Syndrome	HYLS1	AR	Reduced Risk	Personalized Residual Risk: 1 in 52,000
Hyper-Igm Syndrome	CD40LG	XL	Reduced Risk	Personalized Residual Risk: 1 in 1,167,000
Hyperornithinemia-Hyperammonemia- Homocitrullinuria Syndrome	SLC25A15	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.700
Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis	SARS2	AR	Reduced Risk	Personalized Residual Risk: 1 in 23,000
Hypohidrotic Ectodermal Dysplasia 1	EDA	XL	Reduced Risk	Personalized Residual Risk: 1 in 22,000
Hypomagnesemia 1	TRPM6	AR	Reduced Risk	Personalized Residual Risk: 1 in 11,000
Hypomyelinating Leukodystrophy 3	AIMP1	AR	Reduced Risk	Personalized Residual Risk: 1 in 341,000
Hypomyelinating Leukodystrophy 12	VPS11	AR	Reduced Risk	Personalized Residual Risk: 1 in 72,000
Hypoparathyroidism-Retardation-Dysmorphic Syndrome	TBCE	AR	Reduced Risk	Personalized Residual Risk: 1 in 8,100
Hypophosphatasia	ALPL	AR	Reduced Risk	Personalized Residual Risk: 1 in 790
Hypophosphatemic Rickets with Hypercalciuria	SLC34A3	AR	Reduced Risk	Personalized Residual Risk: 1 in 780
Hypotrichosis 8 / Autosomal Recessive Woolly Hair 1	LPAR6	AR	Reduced Risk	Personalized Residual Risk: 1 in 27,000
mmunodeficiency 18	CD3E	AR	Reduced Risk	Personalized Residual Risk: 1 in 73,000
mmunodeficiency 19	CD3D	AR	Reduced Risk	Personalized Residual Risk: 1 in 16,000
nclusion Body Myopathy 2	GNE	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,000
nfantile Cerebral and Cerebellar Atrophy	MED17	AR	Reduced Risk	Personalized Residual Risk: 1 in 129.000
nfantile Neuroaxonal Dystrophy 1 and other PLA2G6-Related Disorders	PLA2G6	AR	Reduced Risk	Personalized Residual Risk: 1 in 690
	CC2D1A	AR	Reduced Risk	Personalized Residual Risk: 1 in 92,000



Intrahepatic Cholestasis	ATP8B1	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,400
Isovaleric Acidemia	ND	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,000
Joubert Syndrome 2	TMEM216	AR	Reduced Risk	Personalized Residual Risk: 1 in 152,000
Joubert Syndrome 4 / Senior-Loken Syndrome 1 / Juvenile Nephronophthisis 1	NPHP1	AR	Reduced Risk	Personalized Residual Risk: 1 in 21,000
Joubert Syndrome 7 / Meckel Syndrome 5 / COACH Syndrome	RPGRIP1L	AR	Reduced Risk	Personalized Residual Risk: 1 in 13,000
Junctional Epidermolysis Bullosa (<i>COL17A1</i> - Related)	COL17A1	AR	Reduced Risk	Personalized Residual Risk: 1 in 5,200
Junctional Epidermolysis Bullosa (<i>ITGA6</i> - Related)	ITGA6	AR	Reduced Risk	Personalized Residual Risk: 1 in 125,000
Junctional Epidermolysis Bullosa (<i>ITGB4-</i> Related)	ITGB4	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,400
Junctional Epidermolysis Bullosa (<i>LAMA3</i> - Related)	LAMA3	AR	Reduced Risk	Personalized Residual Risk: 1 in 21,000
Junctional Epidermolysis Bullosa (<i>LAMB3-</i> Related)	LAMB3	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,900
Junctional Epidermolysis Bullosa (<i>LAMC2-</i> Related)	LAMC2	AR	Reduced Risk	Personalized Residual Risk: 1 in 77.000
Kohlschutter-Tonz Syndrome	ROGDI	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,300
Krabbe Disease	GALC	AR	Reduced Risk	Personalized Residual Risk: 1 in 860
Lamellar Ichthyosis, Type 1	TGM1	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,500
Laron Dwarfism	GHR	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,700
Leber Congenital Amaurosis 10 and Other CEP290-Related Ciliopathies	CEP290	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,100
Leber Congenital Amaurosis 13	RDH12	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,600
Leber Congenital Amaurosis 15 / Retinitis Pigmentosa 14	TULP1	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,800
Leber Congenital Amaurosis 2 / Retinitis Pigmentosa 20	RPE65	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,400
Leber Congenital Amaurosis 4	AIPL1	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,100
Leber Congenital Amaurosis 5	LCA5	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,200
Leber Congenital Amaurosis 8 / Retinitis Pigmentosa 12 / Pigmented Paravenous Chorioretinal Atrophy	CRB1	AR	Reduced Risk	Personalized Residual Risk: 1 in 990
Leigh Syndrome (<i>NDUFS7</i> -Related)	NDUFS7	AR	Reduced Risk	Personalized Residual Risk: 1 in 26,000
Leigh Syndrome (SURF1-Related)	SURF1	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,400
Leigh Syndrome, French-Canadian Type	LRPPRC	AR	Reduced Risk	Personalized Residual Risk: 1 in 32,000
Lethal Congenital Contracture Syndrome 1 / Lethal Arthrogryposis with Anterior Horn Cell Disease	GLE1	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,800
Lethal Congenital Contracture Syndrome 2	ERBB3	AR	Reduced Risk	Personalized Residual Risk: 1 in 36,000
Lethal Congenital Contracture Syndrome 3	PIP5K1C	AR	Reduced Risk	Personalized Residual Risk: 1 in 151,000
Leukoencephalopathy with Vanishing White Matter	EIF2B5	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,300
Limb-Girdle Muscular Dystrophy, Type 2A	CAPN3	AR	Reduced Risk	Personalized Residual Risk: 1 in 960
Limb-Girdle Muscular Dystrophy, Type 2B	DYSF	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,100
Limb-Girdle Muscular Dystrophy, Type 2C	SGCG	AR	Reduced Risk	Personalized Residual Risk: 1 in 4.900
Limb-Girdle Muscular Dystrophy, Type 2D	SGCA	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.500
Limb-Girdle Muscular Dystrophy, Type 2E	SGCB	AR	Reduced Risk	Personalized Residual Risk: 1 in 31,000
Limb-Girdle Muscular Dystrophy, Type 2F	SGCD	AR	Reduced Risk	Personalized Residual Risk: 1 in 52.000
Limb-Girdle Muscular Dystrophy, Type 2H	TRIM32	AR	Reduced Risk	Personalized Residual Risk: 1 in 10,000
Limb-Girdle Muscular Dystrophy, Type 21	FKRP	AR	Reduced Risk	Personalized Residual Risk: 1 in 550
Limb-Girdle Muscular Dystrophy, Type 2L	ANO5	AR	Reduced Risk	Personalized Residual Risk: 1 in 660
Lipoamide Dehydrogenase Deficiency	DLD	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.300
Lipoid Adrenal Hyperplasia	STAR	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.300
-ipora Aurenai riyperpiasia	JIAK	AK	REQUCED RISK	Fei sonauzeu Residual RISK: 1 III 2,400



Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency	HADHA	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.900
Lowe Syndrome	OCRL	XL	Reduced Risk	Personalized Residual Risk: 1 in 1.375.000
Lysinuric Protein Intolerance	SLC7A7	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.000
Malonyl-CoA Decarboxylase Deficiency	MLYCD	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,800
Maple Syrup Urine Disease, Type 1a	BCKDHA	AR	Reduced Risk	Personalized Residual Risk: 1 in 5,100
Maple Syrup Urine Disease, Type 1b	BCKDHB	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,100
Maple Syrup Urine Disease, Type 2	DBT	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.600
Meckel Syndrome 1 / Bardet-Biedl Syndrome 13	MKS1	AR	Reduced Risk	Personalized Residual Risk: 1 in 1700
Medium Chain Acyl-CoA Dehydrogenase Deficiency	ACADM	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,300
MEDNIK Syndrome	AP1S1	AR	Reduced Risk	Personalized Residual Risk: 1 in 211,000
Megalencephalic Leukoencephalopathy with Subcortical Cysts	MLC1	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,300
Megaloblastic Anemia 1	AMN	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,300
Menkes Disease	ATP7A	XL	Reduced Risk	Personalized Residual Risk: 1 in 172,000
Metachromatic Leukodystrophy	ARSA	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,000
Methionine Adenosyltransferase I/III Deficiency	MATIA	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,900
Methylmalonic Acidemia (MMAA-Related)	MMAA	AR	Reduced Risk	Personalized Residual Risk: 1 in 15,000
Methylmalonic Acidemia (MMAB-Related)	MMAB	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,400
Methylmalonic Acidemia (MUT-Related)	MUT	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,300
Methylmalonic Aciduria and Homocystinuria, Cobalamin C Type	MMACHC	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,800
Methylmalonic Aciduria and Homocystinuria, Cobalamin D Type	MMADHC	AR	Reduced Risk	Personalized Residual Risk: 1 in 219,000
Methylmalonic Aciduria and Homocystinuria, Cobalamin F Type	LMBRD1	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,600
Methylmalonyl-CoA Epimerase Deficiency	MCEE	AR	Reduced Risk	Personalized Residual Risk: 1 in 98,000
Microphthalmia / Anophthalmia	VSX2	AR	Reduced Risk	Personalized Residual Risk: 1 in 40,000
Mitochondrial Complex I Deficiency (<i>ACAD9-</i> Related)	ACAD9	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,800
Mitochondrial Complex I Deficiency (<i>NDUFA11</i> - Related)	NDUFA11	AR	Reduced Risk	Personalized Residual Risk: 1 in 414,000
Mitochondrial Complex I Deficiency (<i>NDUFAF5</i> - Related)	NDUFAF5	AR	Reduced Risk	Personalized Residual Risk: 1 in 9,800
Mitochondrial Complex I Deficiency (<i>NDUFS6</i> - Related)	NDUFS6	AR	Reduced Risk	Personalized Residual Risk: 1 in 353,000
Mitochondrial Complex I Deficiency (<i>NDUFV1-</i> Related)	NDUFV1	AR	Reduced Risk	Personalized Residual Risk: 1 in 870
Mitochondrial Complex Deficiency / Leigh Syndrome (<i>FOXRED1</i> -Related)	FOXRED1	AR	Reduced Risk	Personalized Residual Risk: 1 in 7,900
Mitochondrial Complex Deficiency / Leigh Syndrome (<i>NDUFAF2</i> -Related)	NDUFAF2	AR	Reduced Risk	Personalized Residual Risk: 1 in 168,000
Mitochondrial Complex Deficiency / Leigh Syndrome (<i>NDUFS4</i> -Related)	NDUFS4	AR	Reduced Risk	Personalized Residual Risk: 1 in 41,000
Mitochondrial Complex IV Deficiency (<i>COX6B1-</i> related)	COX6B1	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,116,000
Mitochondrial Complex IV Deficiency (<i>APOPT1-</i> Related)	APOPT1	AR	Reduced Risk	Personalized Residual Risk: 1 in 9,200
Mitochondrial Complex IV Deficiency (<i>PET100-</i> Related)	PET100	AR	Reduced Risk	Personalized Residual Risk: 1 in 469,000
Mitochondrial Complex IV Deficiency (<i>SCO1</i> - related)	SCO1	AR	Reduced Risk	Personalized Residual Risk: 1 in 13,000
Mitochondrial Complex IV Deficiency / Leigh Syndrome (<i>COX10</i> -Related)	COX10	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.400
Mitochondrial DNA Depletion Syndrome 2	TK2	AR	Reduced Risk	Personalized Residual Risk: 1 in 4.900
Mitochondrial DNA Depletion Syndrome 3	DGUOK	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.200
Mitochondrial DNA Depletion Syndrome 4A and 4B and other <i>POLG</i> -Related Disorders	POLG	AR	Reduced Risk	Personalized Residual Risk: 1 in 320
Mitochondrial DNA Depletion Syndrome 5	SUCLA2	AR	Reduced Risk	Personalized Residual Risk: 1 in 45,000



Mitochondrial DNA Depletion Syndrome 6 / Navajo Neurohepatopathy	MPV17	AR	Reduced Risk	Personalized Residual Risk: 1 in 4.400
Mitochondrial Myopathy and Sideroblastic Anemia 1	PUS1	AR	Reduced Risk	Personalized Residual Risk: 1 in 320,000
Mitochondrial Trifunctional Protein Deficiency (<i>HADHB</i> -Related)	HADHB	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.000
Molybdenum Cofactor Deficiency A	MOCS1	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,900
Mucolipidosis II / IIIA	GNPTAB	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,100
Mucolipidosis III Gamma	GNPTG	AR	Reduced Risk	Personalized Residual Risk: 1 in 68,000
Mucolipidosis IV	MCOLN1	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,100
Mucopolysaccharidosis Type I	IDUA	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.300
Mucopolysaccharidosis Type II	IDS	XL	Reduced Risk	Personalized Residual Risk: 1 in 76,000
Mucopolysaccharidosis Type IIIA	SGSH	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,600
Mucopolysaccharidosis Type IIIB	NAGLU	AR	Reduced Risk	Personalized Residual Risk: 1 in 950
Mucopolysaccharidosis Type IIIC	HGSNAT	AR	Reduced Risk	Personalized Residual Risk: 1 in 3,200
Mucopolysaccharidosis Type IIID	GNS	AR	Reduced Risk	Personalized Residual Risk: 1 in 137.000
Mucopolysaccharidosis Type IVa	GALNS	AR	Reduced Risk	Personalized Residual Risk: 1 in 690
Mucopolysaccharidosis Type IVb / GM1 Gangliosidosis	GLB1	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,700
Mucopolysaccharidosis type IX	HYAL1	AR	Reduced Risk	Personalized Residual Risk: 1 in 149.000
Mucopolysaccharidosis type VI	ARSB	AR	Reduced Risk	Personalized Residual Risk: 1 in 1.300
Mucopolysaccharidosis VII	GUSB	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,600
Mulibrey Nanism	TRIM37	AR	Reduced Risk	Personalized Residual Risk: 1 in 31,000
Multiple Congenital Anomalies-Hypotonia- Seizures Syndrome 1	PIGN	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,800
Multiple Pterygium Syndrome	CHRNG	AR	Reduced Risk	Personalized Residual Risk: 1 in 9.900
Multiple Sulfatase Deficiency	SUMF1	AR	Reduced Risk	Personalized Residual Risk: 1 in 69,000
Muscle-Eye-Brain Disease and Other <i>POMGNT1-</i> Related Congenital Muscular Dystrophy- Dystroglycanopathies	POMGNT1	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,200
Myoneurogastrointestinal Encephalopathy	TYMP	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,100
Myotubular Myopathy 1	MTM1	XL	Reduced Risk	Personalized Residual Risk: 1 in 192,000
N-Acetylglutamate Synthase Deficiency	NAGS	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.200
Nemaline Myopathy 2	NEB	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,400
Nephrogenic Diabetes insipidus (<i>AVPR2-</i> related)/ Nephrogenic Syndrome of Inappropriate Antidiuresis	AVPR2	XL	Reduced Risk	Personalized Residual Risk: 1 in 471,000
Nephrogenic Diabetes Insipidus, Type II	AQP2	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.400
Nephronophthisis 2	INVS	AR	Reduced Risk	Personalized Residual Risk: 1 in 56,000
Nephrotic Syndrome (<i>NPHS1</i> -Related) / Congenital Finnish Nephrosis	NPHS1	AR	Reduced Risk	Personalized Residual Risk: 1 in 920
Nephrotic Syndrome (<i>NPHS2</i> -Related) / Steroid-Resistant Nephrotic Syndrome	NPHS2	AR	Reduced Risk	Personalized Residual Risk: 1 in 780
Neurodegeneration due to Cerebral Folate Transport Deficiency	FOLR1	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.700
Neurodevelopmental Disorder with Progressive Microcephaly, Spasticity, and Brain Anomalies	PLAA	AR	Reduced Risk	Personalized Residual Risk: 1 in 229,000
Neuronal Ceroid-Lipofuscinosis (CLN3-Related)	CLN3	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.400
Neuronal Ceroid-Lipofuscinosis (<i>CLN5</i> -Related)	CLN5	AR	Reduced Risk	Personalized Residual Risk: 1 in 4.300
Neuronal Ceroid-Lipofuscinosis (CLN6-Related)	CLN6	AR	Reduced Risk	Personalized Residual Risk: 1 in 8.600
	CLN8	AR	Reduced Risk	Personalized Residual Risk: 1 in 3,100
•				
Neuronal Ceroid-Lipofuscinosis (<i>MFSD8</i> - Related)	MFSD8	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,200
Neuronal Ceroid-Lipofuscinosis (<i>CLN8</i> -Related) Neuronal Ceroid-Lipofuscinosis (<i>MFSD8</i> - Related) Neuronal Ceroid-Lipofuscinosis (<i>PPT</i> 1-Related)	MFSD8 PPT1 TPP1	AR AR AR	Reduced Risk Reduced Risk Reduced Risk	Personalized Residual Risk: 1 in 6,200 Personalized Residual Risk: 1 in 7,500



Niemann-Pick Disease, Type C (<i>NPC1</i> -Related)	NPC1	AR	Reduced Risk	Personalized Residual Risk: 1 in 690
Niemann-Pick Disease, Type C (<i>NPC2</i> -Related)	NPC2	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,600
Nijmegen Breakage Syndrome	NBN	AR	Reduced Risk	Personalized Residual Risk: 1 in 14,000
Non-Syndromic Hearing Loss (GJB2-Related)	GJB2	AR	Reduced Risk	Personalized Residual Risk: 1 in 600
Oculocutaneous Albinism, Type IA / IB	TYR	AR	Reduced Risk	Personalized Residual Risk: 1 in 240
Oculocutaneous Albinism, Type IV	SLC45A2	AR	Reduced Risk	Personalized Residual Risk: 1 in 830
Odonto-Onycho-Dermal Dysplasia / Schopf- Schulz-Passarge Syndrome	WNT10A	AR	Reduced Risk	Personalized Residual Risk: 1 in 1.900
Omenn Syndrome (<i>RAG2</i> -Related)	RAG2	AR	Reduced Risk	Personalized Residual Risk: 1 in 17,000
Omenn Syndrome / Severe Combined Immunodeficiency, Athabaskan-Type	DCLRE1C	AR	Reduced Risk	Personalized Residual Risk: 1 in 5,500
Omenn Syndrome and other <i>RAG1</i> -Related Disorders	RAG1	AR	Reduced Risk	Personalized Residual Risk: 1 in 850
Ornithine Aminotransferase Deficiency	OAT	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,100
Ornithine Transcarbamylase Deficiency	OTC	XL	Reduced Risk	Personalized Residual Risk: 1 in 103,000
Osteogenesis Imperfecta, Type XI	FKBP10	AR	Reduced Risk	Personalized Residual Risk: 1 in 9.500
Osteopetrosis 1	TCIRG1	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,700
Osteopetrosis 8	SNX10	AR	Reduced Risk	Personalized Residual Risk: 1 in 16,000
Otospondylomegaepiphyseal Dysplasia / Deafness / Fibrochondrogenesis 2	COL11A2	AR	Reduced Risk	Personalized Residual Risk: 1 in 2.700
Papillon-Lefevre Syndrome	CTSC	AR	Reduced Risk	Personalized Residual Risk: 1 in 5,000
Pendred Syndrome	SLC26A4	AR	Reduced Risk	Personalized Residual Risk: 1 in 390
Peroxisome Biogenesis Disorder 3A and 3B	PEX12	AR	Reduced Risk	Personalized Residual Risk: 1 in 30,000
Peroxisome Biogenesis Disorder 7A and 7B	PEX26	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.300
Phenylalanine Hydroxylase Deficiency	PAH	AR	Reduced Risk	Personalized Residual Risk: 1 in 340
Polycystic Kidney Disease, Autosomal Recessive	PKHD1	AR	Reduced Risk	Personalized Residual Risk: 1 in 450
Polyglandular Autoimmune Syndrome, Type 1	AIRE	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,300
Pontocerebellar Hypoplasia, Type 1A	VRK1	AR	Reduced Risk	Personalized Residual Risk: 1 in 25.000
Pontocerebellar Hypoplasia, Type 1B	EXOSC3	AR	Reduced Risk	Personalized Residual Risk: 1 in 10.000
Pontocerebellar Hypoplasia, Type 2A and Type 4	TSEN54	AR	Reduced Risk	Personalized Residual Risk: 1 in 4.700
Pontocerebellar Hypoplasia, Type 2E	VPS53	AR	Reduced Risk	Personalized Residual Risk: 1 in 139.000
Pontocerebellar Hypoplasia, Type 6	RARS2	AR	Reduced Risk	Personalized Residual Risk: 1 in 8,600
Primary Carnitine Deficiency	SLC22A5	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,500
Primary Ciliary Dyskinesia (CCDC103-Related)	CCDC103	AR	Reduced Risk	Personalized Residual Risk: 1 in 27,000
Primary Ciliary Dyskinesia (CCDC151-Related)	CCDC151	AR	Reduced Risk	Personalized Residual Risk: 1 in 59,000
Primary Ciliary Dyskinesia (CCDC39-Related)	CCDC39	AR	Reduced Risk	Personalized Residual Risk: 1 in 12,000
Primary Ciliary Dyskinesia (DNAH5-Related)	DNAH5	AR	Reduced Risk	Personalized Residual Risk: 1 in 1.500
Primary Ciliary Dyskinesia (DNA/1-Related)	DNAl1	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.000
Primary Ciliary Dyskinesia (DNA/2-Related)	DNAI2	AR	Reduced Risk	Personalized Residual Risk: 1 in 76,000
Primary Ciliary Dyskinesia (<i>RSPHg</i> -Related)	RSPH9	AR	Reduced Risk	Personalized Residual Risk: 1 in 15,000
Primary Coenzyme Q10 Deficiency 7	COQ4	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.300
Primary Congenital Glaucoma 3A	CYP1B1	AR	Reduced Risk	Personalized Residual Risk: 1 in 880
Primary Hyperoxaluria, Type 1	AGXT	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,900
Primary Hyperoxaluria, Type 2	GRHPR	AR	Reduced Risk	Personalized Residual Risk: 1 in 11,000
Primary Hyperoxaluria, Type 3	HOGA1	AR	Reduced Risk	Personalized Residual Risk: 1 in 2.400
Progressive Cerebello-Cerebral Atrophy	SEPSECS	AR	Reduced Risk	Personalized Residual Risk: 1 in 2.400
Progressive Familial Intrahepatic Cholestasis, Type 2	ABCB11	AR	Reduced Risk	Personalized Residual Risk: 1 in 950
Progressive Myoclonic Epilepsy, Type 1B	PRICKLE1	AR	Reduced Risk	Personalized Residual Risk: 1 in 98,000
Progressive Pseudorheumatoid Dysplasia	WISP3	AR	Reduced Risk	Personalized Residual Risk: 1 in 5,600
Prolidase Deficiency	PEPD	AR	Reduced Risk	Personalized Residual Risk: 1 in 5,100



Propionic Acidemia (PCCA-Related)	PCCA	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,100
Propionic Acidemia (PCCB-Related)	PCCB	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.200
Pulmonary Surfactant Dysfunction	ABCA3	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,200
Pycnodysostosis	CTSK	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,000
Pyridoxamine 5'-Phosphate Oxidase Deficiency	PNPO	AR	Reduced Risk	Personalized Residual Risk: 1 in 10,000
Pyridoxine-Dependent Epilepsy	ALDH7A1	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,100
Pyruvate Carboxylase Deficiency	PC	AR	Reduced Risk	Personalized Residual Risk: 1 in 8,000
Pyruvate Dehydrogenase E1-Alpha Deficiency	PDHA1	XL	Reduced Risk	Personalized Residual Risk: 1 in 139.000
Pyruvate Dehydrogenase E1-Beta Deficiency	PDHB	AR	Reduced Risk	Personalized Residual Risk: 1 in 15,000
Renal Tubular Acidosis and Deafness	ATP6V1B1	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,600
Retinitis Pigmentosa 25	EYS	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,800
Retinitis Pigmentosa 26	CERKL	AR	Reduced Risk	Personalized Residual Risk: 1 in 13,000
Retinitis Pigmentosa 28	FAM161A	AR	Reduced Risk	Personalized Residual Risk: 1 in 34,000
Retinitis Pigmentosa 36	PRCD	AR	Reduced Risk	Personalized Residual Risk: 1 in 304,000
Retinitis Pigmentosa 59	DHDDS	AR	Reduced Risk	Personalized Residual Risk: 1 in 422,000
Retinitis Pigmentosa 64 / Bardet-Biedl Syndrome 21 / Cone-Rod Dystrophy 16	C80RF37	AR	Reduced Risk	Personalized Residual Risk: 1 in 50,000
Rh Deficiency Syndrome	RHAG	AR	Reduced Risk	Personalized Residual Risk: 1 in 46,000
Rhizomelic Chondrodysplasia Punctata, Type 1	PEX7	AR	Reduced Risk	Personalized Residual Risk: 1 in 7,200
Rhizomelic Chondrodysplasia Punctata, Type 3	AGPS	AR	Reduced Risk	Personalized Residual Risk: 1 in 620,000
Roberts Syndrome	ESCO2	AR	Reduced Risk	Personalized Residual Risk: 1 in 139.000
Salla Disease	SLC17A5	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.300
Salt and Pepper Developmental Regression Syndrome	ST3GAL5	AR	Reduced Risk	Personalized Residual Risk: 1 in 15.000
Sandhoff Disease	HEXB	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,400
Schimke Immunoosseous Dysplasia	SMARCAL1	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.800
Seckel Syndrome 5 / Microcephaly 9	CEP152	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,700
Segawa Syndrome	TH	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,100
Sepiapterin Reductase Deficiency	SPR	AR	Reduced Risk	Personalized Residual Risk: 1 in 25.000
Severe Combined Immunodeficiency (<i>IL7R-</i> Related)	IL7R	AR	Reduced Risk	Personalized Residual Risk: 1 in 20,000
Severe Combined Immunodeficiency (<i>JAK3-</i> Related)	JAK3	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,100
Severe Combined Immunodeficiency (<i>PTPRC</i> - Related)	PTPRC	AR	Reduced Risk	Personalized Residual Risk: 1 in 8,500
Severe Congenital Neutropenia 4	G6PC3	AR	Reduced Risk	Personalized Residual Risk: 1 in 10,000
Severe Neonatal Hyperparathyroidism	CASR	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,700
Short Stature, Onychodysplasia, Facial Dysmorphism, and Hypotrichosis	POC1A	AR	Reduced Risk	Personalized Residual Risk: 1 in 108,000
Short-Chain Acyl-CoA Dehydrogenase Deficiency	ACADS	AR	Reduced Risk	Personalized Residual Risk: 1 in 660
Shwachman-Diamond Syndrome	SBDS	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,700
Sialidosis, Type I and Type II	NEU1	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,000
Sjogren-Larsson Syndrome	ALDH3A2	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.500
Smith-Lemli-Opitz Syndrome	DHCR7	AR	Reduced Risk	Personalized Residual Risk: 1 in 750
Spastic Paraplegia 15	ZFYVE26	AR	Reduced Risk	Personalized Residual Risk: 1 in 46,000
Spastic Tetraplegia, Thin Corpus Callosum, and Progressive Microcephaly	SLC1A4	AR	Reduced Risk	Personalized Residual Risk: 1 in 80,000
Spherocytosis, Type 5	EPB42	AR	Reduced Risk	Personalized Residual Risk: 1 in 2.500
Spinal Muscular Atrophy with Respiratory Distress 1 / Charcot-Marie-Tooth Disease, Type 2S	IGHMBP2	AR	Reduced Risk	Personalized Residual Risk: 1 in 1200
Spinocerebellar Ataxia with Axonal Neuropathy 3	COA7	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,400
Spondylocostal Dysostosis 1	DLL3	AR	Reduced Risk	Personalized Residual Risk: 1 in 7,200



Spondylometaepiphyseal Dysplasia (<i>DDR2-</i> Related)	DDR2	AR	Reduced Risk	Personalized Residual Risk: 1 in 236,000
Spondylothoracic Dysostosis	MESP2	AR	Reduced Risk	Personalized Residual Risk: 1 in 233.000
Steel Syndrome	COL27A1	AR	Reduced Risk	Personalized Residual Risk: 1 in 93.000
Stuve-Wiedemann Syndrome	LIFR	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,000
Sulfate Transporter-Related Osteochondrodysplasia	SLC26A2	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,800
				Tay-Sachs disease enzyme: Non-carrier
				White blood cells: Non-carrier
				 Hex A%: 68.0% (Non-carrier : 55.0 - 72.0% Carrier: <50%) Total. hexosaminidase activity: 1692 nmol/hr/mg
Tay-Sachs Disease	HEXA	AR	Reduced Risk	Plasma: Non-carrier
				 Hex A%: 63.5 (Non-carrier : 58.0 - 72.0%; Carrier: <54%) Total hexosaminidase activity: 559 nmol/hr/ml
				HEXA Sequencing: Negative Personalized Residual Risk: 1 in 1.000
Thiamine-Responsive Megaloblastic Anemia Syndrome	SLC19A2	AR	Reduced Risk	Personalized Residual Risk: 1 in 5.200
Thyroid Dyshormonogenesis 1	SLC5A5	AR	Reduced Risk	Personalized Residual Risk: 1 in 4.300
Thyroid Dyshormonogenesis 2A	TPO	AR	Reduced Risk	Personalized Residual Risk: 1 in 910
Thyroid Dyshormonogenesis 3	TG	AR	Reduced Risk	Personalized Residual Risk: 1 in 850
Thyroid Dyshormonogenesis 4	IYD	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,800
Thyroid Dyshormonogenesis 5	DUOXA2	AR	Reduced Risk	Personalized Residual Risk: 1 in 29,000
Thyroid Dyshormonogenesis 6	DUOX2	AR	Reduced Risk	Personalized Residual Risk: 1 in 190
Trichohepatoenteric Syndrome 1	TTC37	AR	Reduced Risk	Personalized Residual Risk: 1 in 7.700
Tyrosinemia, Type I	FAH	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,900
Tyrosinemia, Type II	TAT	AR	Reduced Risk	Personalized Residual Risk: 1 in 4.800
Tyrosinemia, Type III	HPD	AR	Reduced Risk	Personalized Residual Risk: 1 in 15,000
Usher Syndrome, Type IB	MY07A	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,000
Usher Syndrome, Type IC	USH1C	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,600
Usher Syndrome, Type ID	CDH23	AR	Reduced Risk	Personalized Residual Risk: 1 in 690
Usher Syndrome, Type IF	PCDH15	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,000
Usher Syndrome, Type IIA	USH2A	AR	Reduced Risk	Personalized Residual Risk: 1 in 290
Usher Syndrome, Type III	CLRN1	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,300
Very Long Chain Acyl-CoA Dehydrogenase Deficiency	ACADVL	AR	Reduced Risk	Personalized Residual Risk: 1 in 920
Vitamin D-Dependent Rickets, Type I	CYP27B1	AR	Reduced Risk	Personalized Residual Risk: 1 in 5,000
Vitamin D-Resistant Rickets, Type IIA	VDR	AR	Reduced Risk	Personalized Residual Risk: 1 in 17,000
Walker-Warburg Syndrome and Other <i>FKTN</i> - Related Dystrophies	FKTN	AR	Reduced Risk	Personalized Residual Risk: 1 in 4,200
Werner Syndrome	WRN	AR	Reduced Risk	Personalized Residual Risk: 1 in 9,200
Wilson Disease	ATP7B	AR	Reduced Risk	Personalized Residual Risk: 1 in 240
Wiskott-Aldrich Syndrome (WAS-Related)	WAS	XL	Reduced Risk	Personalized Residual Risk: 1 in 1,203,000
Wolcott-Rallison Syndrome	EIF2AK3	AR	Reduced Risk	Personalized Residual Risk: 1 in 22,000
Wolman Disease / Cholesteryl Ester Storage Disease	LIPA	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,100
Woodhouse-Sakati Syndrome	DCAF17	AR	Reduced Risk	Personalized Residual Risk: 1 in 81,000
X-Linked Juvenile Retinoschisis	RS1	XL	Reduced Risk	Personalized Residual Risk: 1 in 40,000
X-Linked Severe Combined Immunodeficiency	IL2RG	XL	Reduced Risk	Personalized Residual Risk: 1 in 250,000



Xeroderma Pigmentosum, Group A	XPA	AR	Reduced Risk	Personalized Residual Risk: 1 in 11,000
Xeroderma Pigmentosum, Group C	XPC	AR	Reduced Risk	Personalized Residual Risk: 1 in 12,000
Xeroderma Pigmentosum, Group G	ERCC5	AR	Reduced Risk	Personalized Residual Risk: 1 in 3.000
Zellweger Syndrome Spectrum (PEX10-Related)	PEX10	AR	Reduced Risk	Personalized Residual Risk: 1 in 6,300
Zellweger Syndrome Spectrum (PEX1-Related)	PEX1	AR	Reduced Risk	Personalized Residual Risk: 1 in 2,000
Zellweger Syndrome Spectrum (PEX2-Related)	PEX2	AR	Reduced Risk	Personalized Residual Risk: 1 in 77,000
Zellweger Syndrome Spectrum (PEX6-Related)	PEX6	AR	Reduced Risk	Personalized Residual Risk: 1 in 1,600

AR=Autosomal recessive; XL=X-linked

Test methods and comments

Genomic DNA isolated from this patient was analyzed by one or more of the following methodologies, as applicable:

Fragile X CGG Repeat Analysis (Analytical Detection Rate >99%)

PCR amplification using Asuragen, Inc. AmplideX[®]*FMR1* PCR reagents followed by capillary electrophoresis for allele sizing was performed. Samples positive for *FMR1* CGG repeats in the premutation and full mutation size range were further analyzed by Southern blot analysis to assess the size and methylation status of the *FMR1* CGG repeat.

Genotyping (Analytical Detection Rate >99%)

Multiplex PCR amplification and allele specific primer extension analyses using the MassARRAY[®] System were used to identify certain recurrent variants that are complex in nature or are present in low copy repeats. Rare sequence variants may interfere with assay performance.

Multiplex Ligation-Dependent Probe Amplification (MLPA) (Analytical Detection Rate >99%)

MLPA[®] probe sets and reagents from MRC-Holland were used for copy number analysis of specific targets versus known control samples. False positive or negative results may occur due to rare sequence variants in target regions detected by MLPA probes. Analytical sensitivity and specificity of the MLPA method are both 99%.

For alpha thalassemia, the copy numbers of the *HBA1* and *HBA2* genes were analyzed. Alpha-globin gene deletions, triplications, and the Constant Spring (CS) mutation are assessed. This test is expected to detect approximately 90% of all alpha-thalassemia mutations, varying by ethnicity. carriers of alpha-thalassemia with three or more *HBA* copies on one chromosome, and one or no copies on the other chromosome, may not be detected. With the exception of triplications, other benign alpha-globin gene polymorphisms will not be reported. Analyses of *HBA1* and *HBA2* are performed in association with long-range PCR of the coding regions followed by short-read sequencing.

For Duchenne muscular dystrophy, the copy numbers of all *DMD* exons were analyzed. Potentially pathogenic single exon deletions and duplications are confirmed by a second method. Analysis of *DMD* is performed in association with sequencing of the coding regions. For congenital adrenal hyperplasia, the copy number of the *CYP21A2* gene was analyzed. This analysis can detect large deletions typically due to unequal meiotic crossing-over between *CYP21A2* and the pseudogene *CYP21A1P*. Classic 30-kb deletions make up approximately 20% of *CYP21A2* pathogenic alleles. This test may also identify certain point mutations in *CYP21A2* caused by gene conversion events between *CYP21A2* and *CYP21A2* and *CYP21A1P*. Some carriers may not be identified by dosage sensitive methods as this testing cannot detect individuals with two copies (duplication) of the *CYP21A2* gene on one chromosome and loss of *CYP21A2* (deletion) on the other chromosome. Analysis of *CYP21A2* is performed in association with long-range PCR of the coding regions followed by short-read sequencing.

For spinal muscular atrophy (SMA), the copy numbers of the *SMN1* and *SMN2* genes were analyzed. The individual dosage of exons 7 and 8 as well as the combined dosage of exons 1, 4, 6 and 8 of *SMN1* and *SMN2* were assessed. Copy number gains and losses can be detected with this assay. Depending on ethnicity, 6 - 29 % of carriers will not be identified by dosage sensitive methods as this testing cannot detect individuals with two copies (duplication) of the *SMN1* gene on one chromosome and loss of *SMN1* (deletion) on the other chromosome (silent 2+0 carrier) or individuals that carry an intragenic mutation in *SMN1*. Please also note that 2% of individuals diagnosed with SMA have a causative *SMN1* variant that occurred *de novo*, and therefore cannot be picked up by carrier screening in the parents. Analysis of *SMN1* is performed in association with short-read sequencing of exons 2a-7, followed by confirmation using long-range PCR (described below). The presence of the c.'3+80T>G (chr5:70,247,901T>G) variant allele in an individual with Ashkenazi Jewish or Asian ancestry is typically indicative of a duplication of *SMN1*. When present in an Ashkenazi Jewish or Asian individual with two copies of *SMN1*, c.'3+80T>G is likely indicative of a silent (2+0) carrier. In individuals with two copies of *SMN1* with African American, Hispanic or Caucasian ancestry, the presence or absence of c.'3+80T>G significantly increases or decreases, respectively, the likelihood of being a silent 2+0 silent carrier. MLPA for Gaucher disease (*GBA*), cystic fibrosis (*CFTR*, and non-syndromic hearing loss (*GJB2/GJB6*) will only be performed if indicated for

confirmation of detected CNVs. If GBA analysis was performed, the copy numbers of exons 1, 3, 4, and 6 - 10 of the GBA gene (of 11 exons total)



were analyzed. If *CFTR* analysis was performed, the copy numbers of all 27 *CFTR* exons were analyzed. If *GJB2/GJB6* analysis was performed, the copy number of the two *GJB2* exons were analyzed, as well as the presence or absence of the two upstream deletions of the *GJB2* regulatory region, del(*GJB6*-D13S1830) and del(*GJB6*-D13S1854).

Next Generation Sequencing (NGS) (Analytical Detection Rate >95%)

NGS was performed on a panel of genes for the purpose of identifying pathogenic or likely pathogenic variants.

Agilent SureSelectTMXT Low Input technology was used with a custom capture library to target the exonic regions and intron/exon splice junctions of the relevant genes, as well as a number of UTR, intronic or promoter regions that contain previously reported mutations. Libraries were pooled and sequenced on the Illumina NovaSeq 9000 platform, using paired-end 100 bp reads. The sequencing data was analyzed using a custom bioinformatics algorithm designed and validated in house.

The coding exons and splice junctions of the known protein-coding RefSeq genes were assessed for the average depth of coverage (minimum of 20X) and data quality threshold values. Most exons not meeting a minimum of >20X read depth across the exon are further analyzed by Sanger sequencing. Please note that several genomic regions present difficulties in mapping or obtaining read depth >20X. These regions, which are described below, will not be reflexed to Sanger sequencing if the mapping quality or coverage is poor. Any variants identified during testing in these regions are confirmed by a second method and reported if determined to be pathogenic or likely pathogenic. However, as there is a possibility of false negative results within these regions, detection rates and residual risks for these genes have been calculated with the presumption that variants in these exons will not be detected, unless included in the MassARRAY[®] genotyping platform.

Exceptions; ABCD1 (NM 0000333) exons 8 and 9; ACADSB (NM 0016093) chr10;124.810.695-124.810.707 (partial exon 9); ADA (NM 0000222) exon 1; ADAMTS2 (NM_014244 4) exon 1; AGPS (NM_003659.3) chr2:178,257,512-178,257,649 (partial exon 1); ALDH7A1 (NM_001182.4) chr5:125,911,150-125,911,163 (partial exon 7) and chr5:125,896,807-125,896,821 (partial exon 10); ALMS1 (NM_015120.4) chr2:73,612,990-73,613,041 (partial exon 1); APOPT1 (NM_ 032374.4) chr14:104.040.437-104.040.455 (partial exon 3); CDAN1 (NM_138477.2) exon 2; CEP152 (NM_014985.3) chr15:49.061.146-49.061.165 (partial exon 14) and exon 22; CEP290 (NM_025114.3) exon 5, exon 7, chr12:88.519.017-88.519.039 (partial exon 13). chr12:88,514,049-88,514,058 (partial exon 15), chr12:88,502,837-88,502,841 (partial exon 23), chr12:88,481,551-88,481,589 (partial exon 32), chr12:88,471,605-88,471,700 (partial exon 40); CFTR (NM_000492.3) exon 10; COL4A4 (NM_0000924) chr2:227,942,604-227,942,619 (partial exon 25); COX10 (NM_001303.3) exon 6; CYP11B1 (NM_000497.3) exons 3-7; CYP11B2 (NM_000498.3) exons 3-7; DNAl2 (NM_023036.4) chr17:72,308,136-72,308,147 (partial exon 12); DOK7 (NM_173660.4) chr4:3,465,131-3,465,161 (partial exon 1) and exon 2; DUOX2 (NM_014080.4) exons 6-8; EIF2AK3 (NM_004836.5 exon 8; EVC (NM_1537172) exon 1; FH (NM_000143.3) exon 1; GAMT (NM_000156.5 exon 1; GLDC (NM_000170.2) exon 1; GNPTAB (NM_0243124) chr174,837,000-4,837,400 (partial exon 2); GNPTG (NM_0325204) exon 1; GHR (NM_0001634) exon 3; GYS2 (NM_0219573) chr12 21.699.370-21.699.409 (partial exon 12): HGSNAT (NM_152419.2) exon 1: IDS (NM_000202.6 exon 3: ITGB4 (NM_000213.4) chr17:73.749.976-73,750,060 (partial exon 33); JAK3 (NM_000215.3) chr19:17,950,462-17,950,483 (partial exon 10); LIFR (NM_002310.5 exon 19; LMBRD1 (NM_018368.3) chr6:70,459,226-70,459,257 (partial exon 5), chr6:70,447,828-70,447,836 (partial exon 7) and exon 12; LYST (NM_000081.3) chr1 235,944,158-235,944,176 (partial exon 16) and chr1 235,875,350-235,875,362 (partial exon 43); MLYCD (NM_012213,2) chr16:83,933,242-83,933,282 (partial exon 1); MTR (NM_000254 2) chr1 237,024,418-237,024,439 (partial exon 20) and chr1 237,038,019-237,038,029 (partial exon 24); NBEAL2 (NM 015175 2) chr3 47.021.385-47.021.407 (partial exon 1); NEB (NM 001271208.1 exons 82-105; NPC1 (NM 0002714) chr18 21.123.519-21,123,538 (partial exon 14); NPHP1 (NM_000272.3) chr2:110,937,251-110,937,263 (partial exon 3); OCRL (NM_000276.3) chr2:128,674,450-128,674,460 (partial exon 1); PHKB (NM_000293.2) exon 1 and chr16:47,732,498-47,732,504 (partial exon 30); PIGN (NM_176787.4) chr18:59,815,547-59,815,576 (partial exon 8); PIP5K1C (NM_012398.2) exon 1 and chr19;3637602-3637616 (partial exon 17); POU1F1 (NM_000306.3) exon 5; PTPRC (NM_0028384) exons 11 and 23; PUS1 (NM_025215.5 chr12:132,414,446-132,414,532 (partial exon 2); PPGRIP1L (NM_015272.2) exon 23; SGSH (NM_000199.3) chr17;78,194,022-78,194,072 (partial exon 1); SLC6A8 (NM_005629.3) exons 3 and 4; ST3GAL5 (NM_003896.3) exon 1; SURF1 (NM_003172.3) chrg:136,223,269-136,223,307 (partial exon 1); TRPM6 (NM_017662 4) chrg:77,362,800-77,362,811 (partial exon 31); TSEN54 (NM_207346.2) exon 1; TYR (NM_000372.4) exon 5; VWF (NM_000552.3) exons 24-26, chr12:6,125,675-6,125,684 (partial exon 30), chr12:6,121,244-6,121,265 (partial exon 33), and exon 34.

This test will detect variants within the exons and the intron-exon boundaries of the target regions. Variants outside these regions may not be detected, including, but not limited to, UTRs, promoters, and deep intronic areas, or regions that fall into the Exceptions mentioned above. This technology may not detect all small insertion/deletions and is not diagnostic for repeat expansions and structural genomic variation. In addition, a mutation(s) in a gene not included on the panel could be present in this patient.

Variant interpretation and classification was performed based on the American College of Medical Genetics Standards and Guidelines for the Interpretation of Sequence Variants (Richards et al, 2015). All potentially pathogenic variants may be confirmed by either a specific genotyping assay or Sanger sequencing, if indicated. Any benign variants, likely benign variants or variants of uncertain significance identified during this analysis will not be reported.

Next Generation Sequencing for SMN1



Exonic regions and intron/exon splice junctions of *SMN1* and *SMN2* were captured, sequenced, and analyzed as described above. Any variants located within exons 2a-7 and classified as pathogenic or likely pathogenic were confirmed to be in either *SMN1* or *SMN2* using gene-specific long-range PCR analysis followed by Sanger sequencing. Variants located in exon 1 cannot be accurately assigned to either *SMN1* or *SMN2* using our current methodology, and so these variants are considered to be of uncertain significance and are not reported.

Copy Number Variant Analysis (Analytical Detection Rate >95%)

Large duplications and deletions were called from the relative read depths on an exon-by-exon basis using a custom exome hidden Markov model (XHMM) algorithm. Deletions or duplications determined to be pathogenic or likely pathogenic were confirmed by either a custom arrayCGH platform, quantitative PCR, or MLPA (depending on CNV size and gene content). While this algorithm is designed to pick up deletions and duplications of 2 or more exons in length, potentially pathogenic single-exon CNVs will be confirmed and reported, if detected.

Exon Array (Confirmation method) (Accuracy >99%)

The customized oligonucleotide microarray (Oxford Gene Technology) is a highly-targeted exon-focused array capable of detecting medically relevant microdeletions and microduplications at a much higher resolution than traditional aCGH methods. Each array matrix has approximately 180,000 60-mer oligonucleotide probes that cover the entire genome. This platform is designed based on human genome NCBI Build 37 (hg19) and the CGH probes are enriched to target the exonic regions of the genes in this panel.

Quantitative PCR (Confirmation method) (Accuracy >99%)

Th relative quantification PCR is utilized on a Roche Universal Library Probe (UPL) system, which relates the PCR signal of the target region in one group to another. To test for genomic imbalances, both sample DNA and reference DNA is amplified with primer/probe sets that specific to the target region and a control region with known genomic copy number. Relative genomic copy numbers are calculated based on the standard ΔΔCt formula.

Long-Range PCR (Analytical Detection Rate >99%)

Long-range PCR was performed to generate locus-specific amplicons for *CYP21A2, HBA1* and *HBA2* and *GBA*. The PCR products were then prepared for short-read NGS sequencing and sequenced. Sequenced reads were mapped back to the original genomic locus and run through the bioinformatics pipeline. If indicated, copy number from MLPA was correlated with the sequencing output to analyze the results. For *CYP21A2*, a certain percentage of healthy individuals carry a duplication of the *CYP21A2* gene, which has no clinical consequences. In cases where two copies of a gene are located on the same chromosome in tandem, only the second copy will be amplified and assessed for potentially pathogenic variants, due to size limitations of the PCR reaction. However, because these alleles contain at least two copies of the *CYP21A2* gene in tandem, it is expected that this patient has at least one functional gene in the tandem allele and this patient is therefore less likely to be a carrier. When an individual carries both a duplication allele and a pathogenic variant, or multiple pathogenic variants, the current analysis may not be able to determine the phase (cis/trans configuration) of the *CYP21A2* alleles identified. Family studies may be required in certain scenarios where phasing is required to determine the carrier status.

Residual Risk Calculations

Carrier frequencies and detection rates for each ethnicity were calculated through the combination of internal curations of >30,000 variants and genomic frequency data from >138,000 individuals across seven ethnic groups in the gnomAD database. Additional variants in HGMD and novel deleterious variants were also incorporated into the calculation. Residual risk values are calculated using a Bayesian analysis combining the *a priori* risk of being a pathogenic mutation carrier (carrier frequency) and the detection rate. They are provided only as a guide for assessing approximate risk given a negative result, and values will vary based on the exact ethnic background of an individual. This report does not represent medical advice but should be interpreted by a genetic counselor, medical geneticist or physician skilled in genetic result interpretation and the relevant medical literature.

Personalized Residual Risk Calculations

Agilent SureSelectTMXT Low-Input technology was utilized in order to create whole-genome libraries for each patient sample. Libraries were then pooled and sequenced on the Illumina NovaSeq platform. Each sequencing lane was multiplexed to achieve 0.4-2x genome coverage, using paired-end 100 bp reads. The sequencing data underwent ancestral analysis using a customized, licensed bioinformatics algorithm that was validated in house. Identified sub-ethnic groupings were binned into one of 7 continental-level groups (African, East Asian, South Asian, Non-Finnish European, Finnish, Native American, and Ashkenazi Jewish) or, for those ethnicities that matched poorly to the continental-level groups, an 8th "unassigned" group, which were then used to select residual risk values for each gene. For individuals belonging to multiple high-level ethnic groupings, a weighting strategy was used to select the most appropriate residual risk. For genes that had insufficient data to calculate ethnic-specific residual risk values, or for sub-ethnic groupings that fell into the "unassigned" group, a "worldwide" residual risk was used. This "worldwide" residual risk was calculated using data from all available continental-level groups.

Sanger Sequencing (Confirmation method) (Accuracy >99%)



Sanger sequencing, as indicated, was performed using BigDye Terminator chemistry with the ABI 3730 DNA analyzer with target specific amplicons. It also may be used to supplement specific guaranteed target regions that fail NGS sequencing due to poor quality or low depth of coverage (<20 reads) or as a confirmatory method for NGS positive results. False negative results may occur if rare variants interfere with amplification or annealing.

Tay-Sachs Disease (TSD) Enzyme Analysis (Analytical Detection Rate ≥98%)

Hexosaminidase activity and Hex A% activity were measured by a standard heat-inactivation, fluorometric method using artificial 4-MU-β-Nacetyl glucosaminide (4-MUG) substrate. This assay is highly sensitive and accurate in detecting Tay-Sachs carriers and individuals affected with TSD. Normal ranges of Hex A% activity are 55.0-72.0 for white blood cells and 58.0-72.0 for plasma. It is estimated that less than 0.5% of Tay-Sachs carriers have non-carrier levels of percent Hex A activity, and therefore may not be identified by this assay. In addition, this assay may detect individuals that are carriers of or are affected with Sandhoff disease. False positive results may occur if benign variants, such as pseudodeficiency alleles, interfere with the enzymatic assay. False negative results may occur if both *HEXA* and *HEXB* pathogenic or pseudodeficiency variants are present in the same individual.

Please note these tests were developed and their performance characteristics were determined by Sema4 Opco, Inc. They have not been cleared or approved by the FDA. These analyses generally provide highly accurate information regarding the patient's carrier or affected status. Despite this high level of accuracy, it should be kept in mind that there are many potential sources of diagnostic error, including misidentification of samples, polymorphisms, or other rare genetic variants that interfere with analysis. Families should understand that rare diagnostic errors may occur for these reasons.

SELECTED REFERENCES

Carrier Screening

Grody W et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med. 2013 15:482-3.

Fragile X syndrome:

Chen L et al. An information-rich CGG repeat primed PCR that detects the full range of Fragile X expanded alleles and minimizes the need for Southern blot analysis. *J Mol Diag* 2010 12:589-600.

Spinal Muscular Atrophy:

Luo M et al. An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy. *Genet Med.* 2014 16:149-56.

Ashkenazi Jewish Disorders:

Scott SA et al. Experience with carrier screening and prenatal diagnosis for sixteen Ashkenazi Jewish Genetic Diseases. *Hum. Mutat.* 2010 31:1-11.

Duchenne Muscular Dystrophy:

Flanigan KM et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. *Hum Mutat.* 2009 30:1657-66.

Variant Classification:

Richards S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015 May;17(5):405-24 Additional disease-specific references available upon request.





Lab:EZ

Patient Information	Specimen Information	Client Information
14408, DONOR	Specimen: CF308035D Requisition: 3693670	Client #: 48041578 NYNJMAIL GENOMICS, SEMA4
DOB: AGE:	Lab Ref #: 22814107SPB	SEMA4 62 SOUTHFIELD AVE
Gender: M Phone: NG Patient ID: LP2799103	Collected: 08/03/2022 Received: 08/04/2022 / 20:38 EDT Reported: 08/13/2022 / 03:39 EDT	STAMFORD, CT 06902-7229

Ward: SEATSB

Cytogenetic Report

CHROMOSOME ANALYSIS, BLOOD - 14596

CHROMOSOME ANALYSIS, BLOOD

 Order ID:
 22-325329

 Specimen Type:
 Blood

 Clinical Indication:
 Encounter of male for testing for disease carrier status for procrea management.

RESULT:

NORMAL MALE KARYOTYPE

INTERPRETATION:

Chromosome analysis revealed normal G-band patterns within the limits of standard cytogenetic analysis.

Please expect the results of any other concurrent study in a separate report.

NOMENCLATURE:

46,XY

ASSAY INFORMATION:

Method:	G-Band (Digital Analysis: MetaSyst
Cells Counted:	20
Band Level:	500
Cells Analyzed:	5
Cells Karyotyped:	5

This test does not address genetic disorders that cannot be detected by standard cytogenetic methods or rare events such as low level mosaicism or subtle rearrangements.

Guang Li, PhD, FACMG


Electronic Signature: 8/13/2022 2:04 AM

CLIENT SERVICES: 866.697.8378





Patient Information	Specimen Information	Client Information
14408, DONOR	Specimen: CF308035D	Client #: 48041578
14400, DOITOK	Collected: 08/03/2022	GENOMICS, SEMA4
DOB: AGE:	Received: 08/04/2022 / 20:38 EDT	
Gender: M	Reported: 08/13/2022 / 03:39 EDT	
Patient ID: LP2799103		



PERFORMING SITE:

EZ QUEST DIAGNOSTICS/NICHOLS SJC, 33608 ORTEGA HWY, SAN JUAN CAPISTRANO, CA 92675-2042 Laboratory Director: IRINA MARAMICA, MD, PHD, MBA, CLIA: 05D0643352